Last reviewed · How we verify
Hormone Therapy
Hormone therapy replaces or modulates endogenous hormones to treat deficiency states or hormone-sensitive conditions.
Hormone therapy replaces or modulates endogenous hormones to treat deficiency states or hormone-sensitive conditions. Used for Menopausal hormone therapy, Hormone replacement in hypogonadism, Thyroid hormone replacement.
At a glance
| Generic name | Hormone Therapy |
|---|---|
| Also known as | Chemotherapy-Hormones/Steroids, Endocrine Therapy, Hormonal, Hormonal Therapy, hormone treatment |
| Sponsor | Hoffmann-La Roche |
| Drug class | Hormone replacement therapy / Endocrine agent |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | Phase 3 |
Mechanism of action
Hormone therapy works by supplementing or blocking natural hormones (such as estrogen, progesterone, testosterone, or thyroid hormones) to restore physiological balance, alleviate symptoms of deficiency, or inhibit hormone-dependent disease progression. The specific mechanism depends on the hormone class and indication—replacement therapy restores normal levels, while antagonistic approaches block receptor signaling in hormone-sensitive tissues.
Approved indications
- Menopausal hormone therapy
- Hormone replacement in hypogonadism
- Thyroid hormone replacement
- Adrenal insufficiency
Common side effects
- Breast tenderness
- Headache
- Nausea
- Vaginal bleeding
- Thromboembolic events
- Mood changes
Key clinical trials
- A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer (PHASE2)
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Study of a Weight Loss Intervention in People With Endometrial Cancer (EARLY_PHASE1)
- A Natural History of Genetic and Environmental Predictors of Pubertal Timing Among Youth With Obesity
- Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement (NA)
- An Open-label, Randomized, Single-dose, Two-treatment, Four-period, Fully Replicate Crossover Bioequivalence Study in Healthy Female Adult Participants Under Fasting Conditions Comparing the Test Product, Prontogest Solution for IM Injection With the Reference Product, Progesterone Injection (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |